Detalhe da pesquisa
1.
Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor-reactive CD8+ T cells and reprogramming macrophages.
Immunity
; 56(1): 162-179.e6, 2023 01 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36630914
2.
PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells.
Nature
; 610(7930): 161-172, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36171284
3.
PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program.
Nature
; 610(7930): 173-181, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36171288
4.
CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy.
Blood
; 143(21): 2152-2165, 2024 May 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38437725
5.
Microfluidic Squeezing Enables MHC Class I Antigen Presentation by Diverse Immune Cells to Elicit CD8+ T Cell Responses with Antitumor Activity.
J Immunol
; 208(4): 929-940, 2022 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35091434
6.
Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody.
Blood
; 138(25): 2655-2669, 2021 12 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-34280257
7.
The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo.
J Immunol
; 200(7): 2304-2312, 2018 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29453281
8.
Engineering therapeutic bispecific antibodies using CrossMab technology.
Methods
; 154: 21-31, 2019 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30453028
9.
A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease.
J Autoimmun
; 95: 1-14, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30446251
10.
A novel three-dimensional heterotypic spheroid model for the assessment of the activity of cancer immunotherapy agents.
Cancer Immunol Immunother
; 66(1): 129-140, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27858101
11.
Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388).
Eur J Haematol
; 97(5): 461-470, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26993060
12.
Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicity.
J Immunol
; 192(5): 2252-60, 2014 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24489098
13.
A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.
J Biol Chem
; 289(27): 18693-706, 2014 Jul 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-24841203
14.
Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells.
J Autoimmun
; 56: 66-80, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25457307
15.
Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose.
Proc Natl Acad Sci U S A
; 108(31): 12669-74, 2011 Aug 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-21768335
16.
The physiological interactome of TCR-like antibody therapeutics in human tissues.
Nat Commun
; 15(1): 3271, 2024 Apr 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38627373
17.
Myeloid-T cell interplay and cell state transitions associated with checkpoint inhibitor response in melanoma.
Med
; 2024 Apr 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38593812
18.
Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors.
Clin Cancer Res
; 30(8): 1630-1641, 2024 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38319672
19.
Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposure.
Front Oncol
; 14: 1346502, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38577337
20.
Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies.
Blood
; 118(2): 358-67, 2011 Jul 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-21444918